Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

Completed · Phase 2

Conditions studied: Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection

In brief

This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer). Studying samples of blood from HIV-positive patients with cancer in the laboratory may help doctors learn more about changes that occur in the immune system after stem cell transplant.

Key facts

Study ID

NCT00968630

Run by

Fred Hutchinson Cancer Center

People needed

9

Starts

2009-12-17

Expected to finish

2017-03-17

Last updated by the study team

2017-05-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV positive
• Treatment with highly active antiretroviral therapy (HAART) for at least 1 month
• Viral load has decreased by >= 1.5 logs or viral load < 5000 copies/ml plasma on HAART therapy
• Hematologic malignancy associated with a poor prognosis or other diagnosis for which hematopoietic cell therapy (allogeneic or autologous, including gene therapy) is indicated
• Approval for allogenic regimen given at Patient Care Conference
• DONOR: Autologous or allogeneic gene modified cells allowed

You may not qualify if…

• A medical history of noncompliance with HAART or medical therapy
• Inability to provide informed consent
• DONOR: Allogeneic donors must not have HIV infection

Where it is running

• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.